Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
CARGO Therapeutics, Inc. ( (CRGX) ) has shared an announcement.
CARGO Therapeutics, Inc. announced that on August 18, 2025, Concentra Biosciences, LLC completed a tender offer to purchase all outstanding shares of CARGO Therapeutics, resulting in a merger where CARGO became a wholly owned subsidiary of Concentra. The merger led to the delisting of CARGO’s shares from Nasdaq, and the company filed for deregistration with the SEC, indicating a significant operational shift and change in market presence.
The most recent analyst rating on (CRGX) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on CARGO Therapeutics, Inc. stock, see the CRGX Stock Forecast page.
Spark’s Take on CRGX Stock
According to Spark, TipRanks’ AI Analyst, CRGX is a Underperform.
CARGO Therapeutics faces significant challenges with no revenue and increasing losses. The company’s decision to reduce workforce and pipeline efforts reflects financial distress. Although the technical indicators show some short-term upward momentum, the longer-term outlook remains weak. The negative valuation metrics further highlight profitability concerns. The strategic focus on CAR T therapy and potential partnerships may provide future opportunities but require careful financial management.
To see Spark’s full report on CRGX stock, click here.
More about CARGO Therapeutics, Inc.
Average Trading Volume: 1,686,963
Technical Sentiment Signal: Sell
Current Market Cap: $219.6M
For detailed information about CRGX stock, go to TipRanks’ Stock Analysis page.